Association between hypertriglyceridemia and protein oxidation and proinflammatory markers in normocholesterolemic and hypercholesterolemic individuals

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 50-57

  Klafke, Jonatas Zeni ^a,b   Porto, Fernando Garcez ^a,b   Batista, Roselaine ^a,b   Bochi, Guilherme Vargas ^c   Moresco, Rafael Noal ^c   da Luz, Protásio Lemos ^d   Viecili, Paulo Ricardo Nazário ^a,b  

^a UNIVERSIDADE DE CRUZ ALTA   (Brazil)

^b Instituto de Cardiologia de Cruz Alta   (Brazil)

^c FEDERAL UNIVERSITY OF SANTA MARIA   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Advanced oxidation protein products; High sensitivity C reactive protein; Ischemia modified albumin; Nitric oxide

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; C REACTIVE PROTEIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISCHEMIA MODIFIED ALBUMIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRIC OXIDE; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; BRAZIL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INFLAMMATION; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN OXIDATION; SEDENTARY LIFESTYLE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; METABOLISM; MIDDLE AGED; REGRESSION ANALYSIS;

BIOMARKERS; C-REACTIVE PROTEIN; CHOLESTEROL; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; INFLAMMATION; MALE; MIDDLE AGED; NITRIC OXIDE; OXIDATIVE STRESS; REGRESSION ANALYSIS; TRIGLYCERIDES;

EID: 84933055337     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.06.013     Document Type: Article

References (74)

1. Ford E.S., Giles W.H., Dietz W.H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
2. Berglund L., Brunzell J.D., Goldberg A.C., Goldberg I.J., Stalenhoef A. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab 2014, 28:423-437.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002, 106(25):3143-3421.
4. Sarwar N., Danesh J., Eiriksdottir G., et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458.
5. Kolovou G.D., Mikhailidis D.P., Kovar J., et al. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011, 9:258-270.
6. Miller M., Stone N.J., Ballantyne C., et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333.
7. Lacroix S., Rosiers C.D., Tardif J.C., Nigam A. The role of oxidative stress in postprandial endothelial dysfunction. Nutr Res Rev 2012 Dec, 25(2):288-301.
8. Pang J., Chan D.C., Watts G.F. Origin and therapy for hypertriglyceridaemia in type 2 diabetes. World J Diab 2014, 5:165-175.
9. Talayero B.G., Sacks F.M. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011, 13:544-552.
10. Jacobs D.R., Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982, 116:878-885.
11. Luz P.L.D., Favarato D., Faria-Neto Junior J.R., Lemos P., Chagas A.C.P. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics 2008, 63:427-432.
12. Murad M.H., Hazem A., Coto-Yglesias F., et al. The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord 2012, 31(12):2.
13. Nedeljkovic Z.D., Gokce N., Loscalzo J. Mechanisms of oxidative stress and vascular dysfunction. Postgrad Med J 2003, 79:195-200.
14. Stadtman E.R., Levine R.L. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 2003, 25:207-218.
15. Witko-Sarsat V., Friedlander M., Capeillère-Blandin C., et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996, 49:1304-1313.
16. Descamps-Latscha B., Witko-Sarsat V., Nguyen-Khoa T., et al. Advanced oxidation protein products as risk factors for atherosclerotic cardiovascular events in nondiabetic predialysis patients. Am J Kidney Dis 2005, 45(1):39-47.
17. Kasiske B.L. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998, 32:S142-S156.
18. Zhong Y., Wang N., Xu H., Hou X., Xu P., Zhou Z. Ischemia-modified albumin in stable coronary atherosclerotic heart disease: clinical diagnosis and risk stratification. Coron Artery Dis 2012, 23:538-541.
19. Bar-Or D., Lau E., Winkler J.V. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia: a preliminary report. J Emerg Med 2000, 19:311-315.
20. Gottlieb M.G.V., Da Cruz I.B.M., Duarte M.M.F., et al. Associations among metabolic syndrome, ischemia, inflammatory, oxidatives, and lipids biomarkers. J Clin Endocrinol Metab 2010, 95:586-591.
21. Duarte M.M., Rocha J.B., Moresco R.N., et al. Association between ischemia-modified albumin, lipids and inflammation biomarkers in patients with hypercholesterolemia. Clin Biochem 2009 May, 42(7-8):666-671.
22. Armstrong E.J., Morrow D.A., Sabatine M.S. Inflammatory biomarkers in acute coronary syndromes: part I: introduction and cytokines. Circulation 2006, 11:372-375.
23. Li H., Horke S., Förstermann U. Vascular oxidative stress, nitric oxide and atherosclerosis. Atherosclerosis 2014, 237:208-219.
24. Schönfeld P., Wojtczak L. Free Radic Biol Med 2008, 45:231-241.
25. Valli A., Suliman M.E., Meert N., et al. Overestimation of advanced oxidation protein products in uremic plasma due to presence of triglycerides and other endogenous factors. Clin Chim Acta 2007 Apr, 379(1-2):87-94.
26. Wu G.R., Cheserek M., Shi Y.H., Shen L.Y., Yu J., Le G.W. Elevated plasma dityrosine in patients with hyperlipidemia compared to healthy individuals. Ann Nutr Metab 2014 Dec 18, 66(1):44-50.
27. Xavier H.T., Izar M.C., Faria Neto J.R., et al. Sociedade Brasileira de Cardiologia. V Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose. Arq Bras Cardiol 2013, 101:1-20.
28. Akpinar E., Bashan I., Bozdemir N., Saatci E. Which is the best anthropometric technique to identify obesity: body mass index, waist circumference or waist-hip ratio?. Coll Antropol 2007, 31:387-393.
29. Friedwald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972, 18:100-107.
30. Witko-Sarsat V., Friedlander M., Nguyen Khoa T., et al. Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 1998 Sep 1, 161(5):2524-2532.
31. Kaefer M., Piva S.J., De Carvalho J.A., et al. Association between ischemia modified albumin, inflammation and hyperglycemia in type 2 diabetes mellitus. Clin Biochem 2010, 43:450-454.
32. Tatsch E., Bochi G.V., Pereira Rda S., et al. A simple and inexpensive automated technique for measurement of serum nitrite/nitrate. Clin Biochem 2011 Mar, 44(4):348-350.
33. Vassalle C., Pratali L., Boni C., Mercuri A., Ndreu R. An oxidative stress score as a combined measure of the pro-oxidant and anti-oxidant counterparts in patients with coronary artery disease. Clin Biochem 2008, 41:1162-1167.
34. Şerban C., Drăgan S. The relationship between inflammatory and oxidative stress biomarkers, atherosclerosis and rheumatic diseases. Curr Pharm Des 2014, 20(4):585-600.
35. Redón J., Oliva M.R., Tormos C., et al. Antioxidant activities and oxidative stress byproducts in human hypertension. Hypertension 2003, 41:1096-1101.
36. Nordestgaard B.G., Varbo A. Triglycerides and cardiovascular disease. Lancet 2014 Aug 16, 384(9943):626-635.
37. Grzebyk E., Piwowar A. Glycoxidative modification of albumin in medical research. Pol Merkur Lekarski 2013 Apr, 34(202):239-242.
38. Piwowar A. Advanced oxidation protein products. Part I. Mechanism of the formation, characteristics and property. Pol Merkur Lekarski 2010, 28:166-169.
39. Marsche G., Frank S., Hrzenjak A., et al. Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 2009, 104:750-757.
40. da Silva Pereira R., Tatsch E., Bochi G.V., et al. Assessment of oxidative, inflammatory, and fibrinolytic biomarkers and DNA strand breakage in hypercholesterolemia. Inflammation 2013, 36:869-877.
41. Kaneda H., Taguchi J., Ogasawara K., Aizawa T., Ohno M. Increased level of advanced oxidation protein products in patients with coronary artery disease. Atherosclerosis 2002 May, 162(1):221-225.
42. Wu G., Cheserek M.J., Shi Y., Liu J., Wang L., Le G. Comparison of serum lipid and protein oxidation products levels in patients with different types of dyslipidemia. Wei Sheng Yan Jiu 2014 Jul, 43(4):529-534.
43. Apple F.S. Clinical and analytical review of ischemia-modified albumin measured by the albumin cobalt binding test. Adv Clin Chem 2005, 39:1-10.
44. Knapik-Kordecka M., Piwowar A., Zurawska-Płaksej E., Warwas M. Ischemia modified albumin-specific marker in cardiological diagnostics?. Wiad Lek 2008, 61(10-12):263-268.
45. Roy D., Quiles J., Gaze D.C., et al. Role of reactive oxygen species on the formation of the novel diagnostic marker ischemia modified albumin. Heart 2006, 92:113-114.
46. Abramson J.L., Hooper W.C., Jones D.P., et al. Association between novel oxidative stress markers and C-reactive protein among adults without clinical coronary heart disease. Atherosclerosis 2005 Jan, 178(1):115-121.
47. Libby P., Tabas I., Fredman G., Fisher E.A. Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 2014 Jun 6, 114(12):1867-1879.
48. Sakamotok K., Yamamoto Y., Okamatsu H., Okabe M. D-dimer is helpful for differentiating acute aortic dissection and acute pulmonary embolism from acute myocardial infarction. Hell J Cardiol 2011, 52:123-127.
49. Shah T., Casas J.P., Cooper J.A., et al. Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 2009, 38(1):217-231.
50. Francisco G., Hernández C., Simó R. Serum markers of vascular inflammation in dyslipemia. Clin Chim Acta 2006 Jul 15, 369(1):1-16.
51. Zimmermann O., Li K., Zaczkiewicz M., Graf M., Liu Z., Torzewski J. C-reactive protein in human atherogenesis: facts and fiction. Mediators Inflamm 2014, 2014:561428.
52. Victor V.M., Rocha M., Sola E., et al. Oxidative stress, endothelial dysfunction and atherosclerosis. Curr Pharm Des 2009, 15:2988-3002.
53. Wallace J.P., Johnson B., Padilla J., et al. Postprandial lipaemia, oxidative stress and endothelial function: a review. Int J Clin Pract 2010, 64:389-403.
54. Després J.P., Lemieux I. Nature 2006, 444:881-887.
55. Murray T.V., Ahmad A., Brewer A.C. Reactive oxygen at the heart of metabolism. Trends Cardiovasc Med 2014 Apr, 24(3):113-120.
56. Förstermann U. Endothelial NO synthase as a source of NO and superoxide. Eur J Clin Pharmacol 2006, 62:5-12.
57. Laurindo F.R., Fernandes D.C., Amanso A.M., Lopes L.R., Santos C.X. Novel role of protein disulfide isomerase in the regulation of NADPH oxidase activity: pathophysiological implications in vascular diseases. Review. Antioxid Redox Signal 2008 Jun, 10(6):1101-1113. 10.1089/ars.2007.2011.
58. Dominiczak M.H. Risk factors for coronary disease: the time for a paradigm shift?. Clin Chem Lab Med 2001, 39:907-919.
59. Aronis A., Madar A., Tirosh O. Mechanism underlying oxidative stress-mediated lipotoxicity: exposure of J774.2 macrophages to triacylglycerols facilitates mitochondrial reactive oxygen species production and cellular necrosis. Free Radic Biol Med 2005, 38:1221-1230.
60. Rizzo M., Kotur-Stevuljevic J., Berneis K., et al. Atherogenic dyslipidemia and oxidative stress: a new look. Transl Res 2009 May, 153(5):217-223.
61. Toikka J.O., Ahotupa M., Viikari J.S., et al. Constantly low HDL-cholesterol concentration relates to endothelial dysfunction and increased in vivo LDL-oxidation in healthy young men. Atherosclerosis 1999, 147:133-138.
62. Higashi Y., Maruhashi T., Noma K., Kihara Y. Oxidative stress and endothelial dysfunction: clinical evidence and therapeutic implications. Trends Cardiovasc Med 2014 May, 24(4):165-169.
63. Siekmeier R., Grammer T., März W. Roles of oxidants, nitric oxide, and asymmetric dimethylarginine in endothelial function. J Cardiovasc Pharmacol Ther 2008, 13:279-297.
64. Harrison D.G. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Investig 1997, 100:2153-2157.
65. Leite P.F., Liberman M., Sandoli de Brito F., Laurindo F.R. Review. Redox processes underlying the vascular repair reaction. World J Surg 2004 Mar, 28(3):331-336. [Epub 2004 Feb 17].
66. Klafke J.Z., da Silva M.A., Panigas T.F., et al. Effects of Campomanesia xanthocarpa on biochemical, hematological and oxidative stress parameters in hypercholesterolemic patients. J Ethnopharmacol 2010, 127:299-305.
67. Klafke J.Z., Silva M.A., Rossato M.F., et al. Antiplatelet, antithrombotic, and fibrinolytic activities of Campomanesia xanthocarpa. Evid Based Complement Alternat Med 2012, 2012:1-8.
68. Viecili P.R., Borges D.O., Kirsten K., et al. Effects of Campomanesia xanthocarpa on inflammatory processes, oxidative stress, endothelial dysfunction and lipid biomarkers in hypercholesterolemic individuals. Atherosclerosis 2014 May, 234(1):85-92.
69. Viecili P.R.N., Bündchen D.C., Richter C.M., et al. Dose-response curve to exercise in hypertensive individuals: analysis of the number of sessions to the hypotensive effect. Arq Bras Cardiol 2009 May, 92(5):393-399.
70. Richter C.M., Panigas T.F., Bündchen D.C., Dipp T., belli K.C., Viecili P.R.N. Redução dos níveis pressóricos em indivíduos hiper-reativos após treinamento físico aeróbio. Arq Bras Cardiol 2010, 95(2). [São Paulo Aug. 2010 Epub July 09, 2010].
71. Tanaka L.Y., Bechara L.R., Dos Santos A.M., et al. Nitric Oxide 2015 Feb 15, 45:7-14. [Epub 2015 Jan 22]. 10.1016/j.niox.2015.01.003.
72. Tousoulis D., Kampoliam A.M., Tentolouris C., Papageorgiou N., Stefanadis C. The role of nitric oxide on endothelial function. Curr Vasc Pharmacol 2012, 10:4-18.
73. Feron O., Dessy C., Moniotte S., Desager J.P., Balligand J.L. Hipercholesterolemia decrease nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase. J Clin Investig 1999, 03:897-905.
74. Rahman M.M., Varghese Z., Moorhead J.F. Paradoxical increase in nitric oxide synthase activity in hypercholesterolaemic rats with impaired renal function and decreased activity of nitric oxide. Nephrol Dial Transplant 2001, 16:262-268.